These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis. Blair HA Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593 [TBL] [Abstract][Full Text] [Related]
4. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures. Zanwar S; Gertz MA; Muchtar E; Buadi FK; Kourelis T; Gonsalves W; Go RS; Hayman S; Kapoor P; Binder M; Cook J; Dingli D; Leung N; Lin Y; Warsame R; Fonder A; Hobbs M; Hwa YL; Kyle RA; Rajkumar SV; Kumar S; Dispenzieri A Leukemia; 2024 Jun; 38(6):1423-1426. PubMed ID: 38594348 [No Abstract] [Full Text] [Related]
5. Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study. Shen KN; Gao YJ; Chang L; Zhang L; Cao XX; Tian Z; Wang YN; Zhou DB; Li J Haematologica; 2024 Jul; 109(7):2355-2358. PubMed ID: 38546676 [No Abstract] [Full Text] [Related]
7. Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival. Oubari S; Hegenbart U; Schoder R; Steinhardt M; Papathanasiou M; Rassaf T; Thimm A; Hagenacker T; Naser E; Duhrsen U; Reinhardt HC; Kortum M; Agis H; Schonland S; Carpinteiro A Haematologica; 2024 Jan; 109(1):220-230. PubMed ID: 37439344 [TBL] [Abstract][Full Text] [Related]
8. [Interest of daratumumab in refractory AL amyloidosis in a 96-year-old patient]. Vial G; Lafargue A; Mercié P; Duffau P; Ribeiro E Rev Med Interne; 2022 Nov; 43(11):673-676. PubMed ID: 35934598 [TBL] [Abstract][Full Text] [Related]
9. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden. Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522 [TBL] [Abstract][Full Text] [Related]
10. Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma. Kawano Y; Hata H; Takashio S; Tsujita K; Ueda M; Matsuoka M Br J Haematol; 2022 Aug; 198(3):e38-e41. PubMed ID: 35524546 [No Abstract] [Full Text] [Related]
11. A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis. Bellofiore C; Benvenuti P; Mina R; Basset M; Foli A; Nanci M; Nuvolone M; Guida G; Attanasio A; Mussinelli R; Mangiacavalli S; Cartia CS; Masoni V; Palumbo M; Cani L; Oliva S; Consoli U; Conticello C; Di Raimondo F; Arcaini L; Bringhen S; Merlini G; Palladini G; Milani P Hematol Oncol; 2024 Jul; 42(4):e3289. PubMed ID: 38824453 [TBL] [Abstract][Full Text] [Related]
13. AL amyloidosis: Singapore Myeloma Study Group consensus guidelines on diagnosis, treatment and management. Tan M; Chen Y; Ooi M; de Mel S; Tan D; Soekojo C; Tso A; Khoo CY; Tan HZ; Choo J; Lee LK; Diong CP; Goh YT; Hwang W; Linn YC; Ho A; Chng WJ; Nagarajan C Ann Acad Med Singap; 2023 Nov; 52(11):601-624. PubMed ID: 38920149 [TBL] [Abstract][Full Text] [Related]
14. Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis. Kennedy VE; Natsuhara K; Maringanti SA; Shah ND; Arora S; Wolf J; Martin TG; Aras MA; Chung A; Wong SW Curr Probl Cancer; 2023 Jun; 47(3):100953. PubMed ID: 36807996 [TBL] [Abstract][Full Text] [Related]
15. Successful Treatment of Systemic Light Chain Amyloidosis with Liver Involvement using Low-Frequency Daratumumab: A Case Report. Meng X; He J; Cheng F; Yan H; Zhu C; Guo X; Li Y; Cai Z; He D Am J Case Rep; 2024 Jan; 25():e942534. PubMed ID: 38229422 [TBL] [Abstract][Full Text] [Related]
16. Update on the Contemporary Treatment of Light Chain Amyloidosis Including Stem Cell Transplantation. Abdallah M; Sanchorawala V Am J Med; 2022 Apr; 135 Suppl 1():S30-S37. PubMed ID: 35081382 [TBL] [Abstract][Full Text] [Related]
17. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Palladini G; Kastritis E; Maurer MS; Zonder J; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Bumma N; Kaufman JL; Medvedova E; Kovacsovics T; Rosenzweig M; Sanchorawala V; Qin X; Vasey SY; Weiss BM; Vermeulen J; Merlini G; Comenzo RL Blood; 2020 Jul; 136(1):71-80. PubMed ID: 32244252 [TBL] [Abstract][Full Text] [Related]
18. Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study. Zhang Y; Duncanson L; Brayer J; Reu F; Hansen D; Alsina M; Nishihori T; Ochoa-Bayona J; Liu H; Shain K; Thompson Z; Baz R; Blue B Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e770-e776. PubMed ID: 35504808 [TBL] [Abstract][Full Text] [Related]
19. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement. Arnall JR; Usmani SZ; Adamu H; Mishkin J; Bhutani M J Oncol Pharm Pract; 2019 Jun; 25(4):1021-1025. PubMed ID: 30477388 [TBL] [Abstract][Full Text] [Related]
20. Management of AL amyloidosis in 2020. Palladini G; Milani P; Merlini G Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):363-371. PubMed ID: 33275753 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]